BusinessWeek
... to crowning expectations, but the pet matter and products merchandiser lowered profit estimates for the full year, sending shares tumbling in after-hours trading. ...
and more »
Welcome to my new trading blog based of after hours stocks. Please subscribe for updates.
Rambus Inc. (NASDAQ: RMBS) is up over 7% at $18.55 at 2:00 PM EST on 3.6 million shares. This already represents 140% of cipher daily intensity and the reasons cited are rumors of a settlement on a case with NVIDIA Corporation (NASDAQ: NVDA). Be advised that this move now has Rambus at the higher-end of its 52-week trading range of $4.95 to $19.65. NVIDIA shares are down 1% at $13.20 but only on half of a day’s cipher volume. Rambus is one of these highbrowed concept companies which relies on patent and highbrowed concept licenses in the semiconductor and chip sector for effectively every of its revenues. We are also seeing elevated CALL OPTION activity in the August options which suspire this Friday:
STRIKE Volume Op.Int.
$17.00Â Â Â 1,032Â 11,580
$18.00Â Â Â 3,923Â 11,958
$19.00Â Â Â 4,082Â 6,302
$20.00Â Â Â 3,709Â 10,384
SEPTEMBER 2010 CALL option activity is elevated as well:
STRIKE Volume Op.Int.
$18.00Â Â Â 5,021Â 1,485
$19.00Â Â Â 4,640Â 1,092
$20.00Â Â Â 4,039Â 2,917
$21.00Â Â Â 1,110Â 1,078
$22.00Â Â Â 2,640Â 1,926
-JON OGG
We have seen some elevated call option activity in Cameco Corp. (NYSE: CCJ), Canada’s crowning nuclear and metal play. The SET-2009 CALLS have been active while the stock has not. So far we have 577,000 shares traded as of 11:15 AM EST and shares are up 0.5% at $28.25 vs. an average daily volume of most 2 meg shares and a 52-week trading range of $11.78 to $30.83. While there is not firm news, this does come on the heels of news that it has filed a shelf catalogue for an substance of up to C$1 billion of senior unsecured debentures. Here is the SEPT-2009 CALL data:
Strike.. Volume.. Op.Int.
$30.00.. 5,000Â Â 12,979
$31.00.. 12Â Â Â Â Â Â Â Â Â 649
$32.00.. 270Â Â Â Â Â 1,917
$33.00.. 2,495Â Â Â 2,253
JON C. OGG
AUGUST 19, 2009
Cerus Corporation (NASDAQ: CERS) is sight a surge after announcing that the land regulatory body titled Swissmedic has approved the ingest of platelet components aerated with Cerus’ INTERCEPT Blood System. The company noted that this support extends permissible hardware instance for platelets to heptad days with INTERCEPT treatment, compared to five days without treatment. Be advised that the land market is a small market, but is also a key to other market. Cerus shares at 8:48 AM EST have already traded 150,000 shares and the terminal change was up over 30% at $2.35. Average volume is about 370,000 shares and the market cap was only $58 million as of the close yesterday. The 52-week high here is $5,02, so this one is not off its charts. -JON OGG